May 23rd 2022
Society for Cardiovascular Angiography and Interventions
Data from an interim analysis of the DIPRA trial suggest distal radial artery access for cardiac catheterization and resulted in no significant differences in hand function compared to proximal radial artery access.
May 21st 2022
Society for Cardiovascular Angiography and Interventions
Long-term data from the SAFE-PAD trial at SCAI 2022 underlines the noninferiority of paclitaxel-coated devices versus non-drug-coat devices for use in patients with peripheral artery disease.
May 20th 2022
Society for Cardiovascular Angiography and Interventions
An analysis of data from the Fuwai PCI registry details the incidence of adverse events and risk of bleeding associated with clopidogrel monotherapy versus aspirin monotherapy 12 months post-PCI in high-risk patients.
May 20th 2022
Society for Cardiovascular Angiography and Interventions
Chair of the SCAI's writing group for their 2022 guidelines on management of patent foramen ovale, Dr. Clifford Kavinsky, sits down with Practical Cardiology to take part in a Q&A on the guideline's recommendations and the writing process for the SCAI's first PFO guidance.
April 6th 2022
American College of Cardiology
Data from a phase 2b trial of bentracimab presented by Deepak Bhatt, MD, MPH, at ACC.22 demonstrates it the ability for reversing antiplatelet effects in an older population.
April 5th 2022
American College of Cardiology
Don't Miss a Beat hosts Drs. Vaduganathan and Greene provide insight into the results of trials from ACC.22 late-breaking sessions they highlighted in the preview episode they recorded ahead of the American College of Cardiology's 71st Annual Scientific Session.
April 4th 2022
American College of Cardiology
Data from the DIAMOND trial suggests use of patiromer could help patients maintain optimized RAASi therapy, even if they were experiencing or had a history of hyperkalemia.
April 4th 2022
American College of Cardiology
Deepak Bhatt, MD, MPH, breaks down data from the SCORED trial presented at ACC.22, which demonstrated sotagliflozin provided significant benefit in terms of reducing total MACE, total MI, and total stroke, regardless of whether a patient had a history of cardiovascular disease.
April 4th 2022
American College of Cardiology
A large-scale analysis of data from a pair of RCTs and a nonrandomized registry provide insight into the risk of valve deterioration seen with TAVR vs SAVR and to what extent this might influence risk of mortality.